

ISIC-0001-103 (ISIS-4945)

PATENT

In the Claims:

Please cancel claims 1-15 and 27-32.

Please add new claims 33-42 as shown below.

Status of Claims:

1-15 (Cancelled herein)

16-26 (previously cancelled)

27-32 (Cancelled herein)

1
33. (New) A formulation for rectal administration by enema comprising an antisense oligonucleotide, said antisense oligonucleotide comprising (SEQ. ID NO:1).

2
34. (New) A formulation according to claim 33 further comprising at least one penetration enhancer.

3
35. (New) A formulation according to claim 34 wherein said penetration enhancer is a fatty acid, bile salt, chelating agent, surfactant or non-chelating non-surfactant.

4
36. (New) A formulation according to claim 33 wherein said formulation comprises an emulsion.

5
37. (New) A formulation according to claim 33 wherein said formulation comprises a solution.

6
38. (New) A formulation according to claim 36 further comprising at least one penetration enhancer.

ISIC-0001-103 (ISIS-4945)

PATENT

5
7 39. (New) A formulation according to claim 37 further comprising at least one penetration enhancer.

6
8 40. (New) A formulation according to claim 38 wherein said penetration enhancer is a fatty acid, bile salt, chelating agent, surfactant or non-chelating non-surfactant.

7
9 41. (New) A formulation according to claim 39 wherein said penetration enhancer is a fatty acid, bile salt, chelating agent, surfactant or non-chelating non-surfactant.

1
10 42. (New) A formulation according to claim 35 wherein said formulation comprises saline solution.--